Bill
HB 484
Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
2026 Regular Session
Introduced by Jackie Addison and 10 co-sponsors
Maryland modifies corporate income tax treatment of direct-to-consumer pharmaceutical advertising expenses, potentially affecting drug marketing practices and state tax revenue.
Hearing 2/12 at 1:00 p.m.